Albert Invent, which launched an AI model trained on chemical patents and data about 15M molecules, raised a $55M Series B, a source says at a $340M valuation

AI-powered scientific discovery tools are now valued in the hundreds of millions.

Albert Invent, a company that provides AI tools for scientific experiment design, has reportedly raised $55 million in a Series B funding round. The funding values the company at $340 million. Albert Invent's AI model is trained on chemical patents and data encompassing approximately 15 million molecules. Scientists at major manufacturing companies, including Kenvue and Henkel, utilize Albert Invent's platform to assist in their experiment design processes.

This significant Series B funding round underscores continued investor confidence in AI applications within the R&D and chemical sectors. The substantial valuation suggests that the market recognizes the potential for AI to accelerate innovation and reduce time-to-market for new chemical compounds and materials. Albert Invent's focus on chemical patents and molecular data positions it to become a key enabler for companies looking to streamline their discovery pipelines.

The adoption by large manufacturing conglomerates like Kenvue and Henkel indicates a growing trend of specialized AI solutions moving from theoretical promise to practical application in industrial settings. This validates the business model of AI companies catering to niche scientific domains. For researchers, it means access to more powerful tools that can augment their capabilities, potentially leading to faster breakthroughs and more efficient product development cycles.